vs
ACCO BRANDS Corp（ACCO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是ACCO BRANDS Corp的1.8倍（$772.1M vs $428.8M），Revvity净利率更高（12.7% vs 5.0%，领先7.8%），Revvity同比增速更快（5.9% vs -4.3%），过去两年ACCO BRANDS Corp的营收复合增速更高（9.3% vs 9.0%）
ACCO Brands是一家美国跨国企业，由财富品牌旗下的ACCO World与通用装订公司GBC合并组建而成，截至2025年，公司董事长兼首席执行官为Thomas W. Tedford，主营办公文具与办公用品相关业务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ACCO vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$428.8M
营收增速更快
RVTY
高出10.2%
-4.3%
净利率更高
RVTY
高出7.8%
5.0%
两年增速更快
ACCO
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $428.8M | $772.1M |
| 净利润 | $21.3M | $98.4M |
| 毛利率 | 33.6% | — |
| 营业利润率 | 9.3% | 14.5% |
| 净利率 | 5.0% | 12.7% |
| 营收同比 | -4.3% | 5.9% |
| 净利润同比 | 3.4% | 3.9% |
| 每股收益（稀释后） | $0.23 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACCORVTY
| Q4 25 | $428.8M | $772.1M | ||
| Q3 25 | $383.7M | $698.9M | ||
| Q2 25 | $394.8M | $720.3M | ||
| Q1 25 | $317.4M | $664.8M | ||
| Q4 24 | $448.1M | $729.4M | ||
| Q3 24 | $420.9M | $684.0M | ||
| Q2 24 | $438.3M | $691.7M | ||
| Q1 24 | $358.9M | $649.9M |
净利润ACCORVTY
| Q4 25 | $21.3M | $98.4M | ||
| Q3 25 | $4.0M | $46.7M | ||
| Q2 25 | $29.2M | $53.9M | ||
| Q1 25 | $-13.2M | $42.2M | ||
| Q4 24 | $20.6M | $94.6M | ||
| Q3 24 | $9.3M | $94.4M | ||
| Q2 24 | $-125.2M | $55.4M | ||
| Q1 24 | $-6.3M | $26.0M |
毛利率ACCORVTY
| Q4 25 | 33.6% | — | ||
| Q3 25 | 33.0% | 53.6% | ||
| Q2 25 | 32.9% | 54.5% | ||
| Q1 25 | 31.4% | 56.5% | ||
| Q4 24 | 34.7% | — | ||
| Q3 24 | 32.5% | 56.3% | ||
| Q2 24 | 34.8% | 55.7% | ||
| Q1 24 | 30.8% | 54.6% |
营业利润率ACCORVTY
| Q4 25 | 9.3% | 14.5% | ||
| Q3 25 | 6.8% | 11.7% | ||
| Q2 25 | 8.4% | 12.6% | ||
| Q1 25 | -2.1% | 10.9% | ||
| Q4 24 | 9.4% | 16.3% | ||
| Q3 24 | 6.2% | 14.3% | ||
| Q2 24 | -25.4% | 12.4% | ||
| Q1 24 | 1.6% | 6.8% |
净利率ACCORVTY
| Q4 25 | 5.0% | 12.7% | ||
| Q3 25 | 1.0% | 6.7% | ||
| Q2 25 | 7.4% | 7.5% | ||
| Q1 25 | -4.2% | 6.4% | ||
| Q4 24 | 4.6% | 13.0% | ||
| Q3 24 | 2.2% | 13.8% | ||
| Q2 24 | -28.6% | 8.0% | ||
| Q1 24 | -1.8% | 4.0% |
每股收益（稀释后）ACCORVTY
| Q4 25 | $0.23 | $0.86 | ||
| Q3 25 | $0.04 | $0.40 | ||
| Q2 25 | $0.31 | $0.46 | ||
| Q1 25 | $-0.14 | $0.35 | ||
| Q4 24 | $0.21 | $0.77 | ||
| Q3 24 | $0.09 | $0.77 | ||
| Q2 24 | $-1.29 | $0.45 | ||
| Q1 24 | $-0.07 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $664.6M | $7.3B |
| 总资产 | $2.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACCORVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益ACCORVTY
| Q4 25 | $664.6M | $7.3B | ||
| Q3 25 | $644.0M | $7.4B | ||
| Q2 25 | $637.3M | $7.6B | ||
| Q1 25 | $606.1M | $7.6B | ||
| Q4 24 | $606.1M | $7.7B | ||
| Q3 24 | $615.5M | $7.9B | ||
| Q2 24 | $617.1M | $7.9B | ||
| Q1 24 | $758.5M | $7.8B |
总资产ACCORVTY
| Q4 25 | $2.3B | $12.2B | ||
| Q3 25 | $2.3B | $12.1B | ||
| Q2 25 | $2.4B | $12.4B | ||
| Q1 25 | $2.3B | $12.4B | ||
| Q4 24 | $2.2B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B | ||
| Q1 24 | $2.5B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.44× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ACCORVTY
| Q4 25 | $30.6M | $182.0M | ||
| Q3 25 | $71.5M | $138.5M | ||
| Q2 25 | $-38.9M | $134.3M | ||
| Q1 25 | $5.5M | $128.2M | ||
| Q4 24 | $52.7M | $174.2M | ||
| Q3 24 | $92.9M | $147.9M | ||
| Q2 24 | $-25.6M | $158.6M | ||
| Q1 24 | $28.2M | $147.6M |
自由现金流ACCORVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率ACCORVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度ACCORVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率ACCORVTY
| Q4 25 | 1.44× | 1.85× | ||
| Q3 25 | 17.88× | 2.97× | ||
| Q2 25 | -1.33× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 2.56× | 1.84× | ||
| Q3 24 | 9.99× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACCO
| Transferred At Point In Time | $421.6M | 98% |
| Transferred Over Time | $7.2M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
